MYOD1 and Bannayan-Riley-Ruvalcaba syndrome: Thus genotyping for MYOD1 (L122R) mutation may preclude the requirement to perform immunohistochemical analysis in order to identify an aggressive subset of spindle cell and sclerosing RMSs, early on to help inform adoption of appropriate therapeutic regimen.